Dong-A and Shanghai Zhongxi Sunve sign license agreement for Zydena

Published: 2011-08-12 06:56:00

Updated: 2011-08-12 06:56:00

Dong-A Pharmaceutical Co. said Tuesday that it has signed an agreement with Shanghai Zhongxi Sunve Pharmaceutical Co. based in China to market Dong-A’s orally-administered udenafil product, a phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED) in China.

“We...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK